Establishment and maintenance of HIV latency: Model systems and opportunities for intervention

Future Virology

Volumn 5, Issue 1, 2010, Pages 97-109

  Marsden, Matthew D ^a   Zack, Jerome A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Antiretroviral drug; Histone deacetylase; HIV; Immunotoxin; Latency; Macrophage; Persistence; Prostratin; Reservoirs

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; HISTONE DEACETYLASE; HOMALANTHUS MUTANS EXTRACT; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOTOXIN; INTERLEUKIN 17; INTERLEUKIN 2; OKT 3; PLANT EXTRACT; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; VALPROIC ACID; VIRUS DNA;

ACETYLATION; CD4+ T LYMPHOCYTE; CELL LINE; CYTOPENIA; EUPHORBIA; EXPERIMENTAL MODEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMALANTHUS MUTANS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MECHANICS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; SCID MOUSE; UNSPECIFIED SIDE EFFECT; VIRUS LATENCY; VIRUS REPLICATION;

EID: 74049131691     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.70     Document Type: Review

References (134)

1. Piatak M Jr, Saag MS, Yang LC et al.: High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259(5102), 1749-1754 (1993).
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373(6510), 123-126 (1995).
3. Wei X, Ghosh SK, Taylor ME et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373(6510), 117-122 (1995).
4. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271(5255), 1582-1586 (1996).
5. Cavert W, Notermans DW, Staskus K et al.: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276(5314), 960-964 (1997).
6. Fatkenheuer G, Pozniak AL, Johnson MA et al.: Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11(11), 1170-1172 (2005).
7. Grinsztejn B, Nguyen BY, Katlama C et al.: Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet 369(9569), 1261-1269 (2007).
8. Pomerantz Rj, Horn Dl: Twenty years of therapy for HIV-1 infection. Nat. Med. 9(7), 867-873 (2003).
9. Gulick RM, Mellors JW, Havlir D et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. .Engl. J. Med. 337(11), 734-739 (1997).
10. Perelson AS, Essunger P, Cao Y et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387(6629), 188-191 (1997).
11. Hammer SM, Squires KE, Hughes MD et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team. N. .Engl. J. Med. 337(11), 725-733 (1997).
12. Hirsch M, Steigbigel R, Staszewski S et al.: A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J. Infect. Dis. 180(3), 659-665 (1999).
13. Chun T-W, Davey RT, Engel D, Lane HC, Fauci AS: AIDS: re-emergence of HIV after stopping therapy. Nature 401(6756), 874-875 (1999).
14. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS: HIV-1 entry into quiescent primary lymphocytes: molecular ana lysis reveals a labile, latent viral structure. Cell 61(2), 213-222 (1990).
15. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M: Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254(5030), 423-427 (1991).
16. 0 lymphocytes. J. Virol. 73(8), 6526-6532 (1999).
17. + lymphocytes. Nature 426(6968), 853-857 (2003).
18. + T cells. Nature 435(7038), 108-114 (2005).
19. + T cells. J. Virol. 79(4), 2199-2210 (2005).
20. Zack JA, Haislip AM, Krogstad P, Chen IS: Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J. Virol. 66(3), 1717-1725 (1992).
21. Korin YD, Zack JA: Progression to the g1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72(4), 3161-3168 (1998).
22. + T cells. J. Virol. 83(12), 6222-6233 (2009).
23. + T cells but enters naive cells less efficiently than memory cells. J. Virol. 83(9), 4528-4537 (2009).
24. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF: In vivo fate of HIV-1-infected T cells: quantitative ana lysis of the transition to stable latency. Nat. Med. 1(12), 1284-1290 (1995).
25. Finzi D, Hermankova M, Pierson T et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278(5341), 1295-1300 (1997).
26. Wong JK, Hezareh M, Gunthard HF et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278(5341), 1291-1295 (1997).
27. Chun TW, Carruth L, Finzi D et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387(6629), 183-188 (1997). ■■ Provides the first accurate quantification of the latent reservoir.
28. + T cells during primary HIV-1 infection. Proc. Natl Acad. Sci. USA 95(15), 8869-8873 (1998).
29. Strain MC, Little SJ, Daar ES et al.: Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 191(9), 1410-1418 (2005).
30. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5(5), 512-517 (1999). ■■ Provides evidence for the slow in vivo decay rate of latently infected cells in treated patients, indicating that HAART alone is unlikely to clear this reservoir.
31. Chomont N, El-Far M, Ancuta P et al.: HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15(8), 893-900 (2009).
32. + T lymphocytes in vivo. J. Virol. 77(13), 7383-7392 (2003).
33. + T cells in vivo. J. Virol. 78(17), 9105-9114 (2004).
34. Hammarlund E, Lewis MW, Hansen SG et al.: Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9(9), 1131-1137 (2003).
35. Combadiere B, Boissonnas A, Carcelain G et al.: Distinct time effects of vaccination on long-term proliferative and IFN-γ-producing T cell memory to smallpox in humans. J. Exp. Med. 199(11), 1585-1593 (2004).
36. Jordan A, Bisgrove D, Verdin E: HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22(8), 1868-1877 (2003). ■■ Original description of the widely used J-Lat model for HIV latency in Jurkat T cells.
37. Kim YK, Bourgeois CF, Pearson R et al.: Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J. 25(15), 3596-3604 (2006).
38. Marsden MD, Zack JA: Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo. J. Virol. 81(11), 6146-6150 (2007).
39. Koup RA, Ho DD, Poli G, Fauci AS: Isolation and quantitation of HIV in peripheral blood. Curr. Protoc. Immunol. 12(Suppl. 5), 2.1-2.11 (1993).
40. Unutmaz D, Kewalramani VN, Marmon S, Littman DR: Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189(11), 1735-1746 (1999).
41. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155(3), 1151-1164 (1995).
42. Brooks DG, Kitchen SG, Kitchen CM, Scripture-Adams DD, Zack JA: Generation of HIV latency during thymopoiesis. Nat. Med. 7(4), 459-464 (2001).
43. Linton PJ, Dorshkind K: Age-related changes in lymphocyte development and function. Nat. Immunol. 5(2), 133-139 (2004).
44. Adams M, Sharmeen L, Kimpton J et al.: Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc. Natl Acad. Sci. USA 91(9), 3862-3866 (1994).
45. + T cells. PLoS Pathog. 2(7), e68 (2006).
46. Nabel G, Baltimore D: An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326(6114), 711-713 (1987).
47. Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP: The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 6(3), 235-244 (1997).
48. Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR: Identification of a putative regulator of early T cell activation genes. Science 241(4862), 202-205 (1988).
49. + T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78(12), 6122-6133 (2004).
50. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F: HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110(4), 521-529 (2002).
51. Lenasi T, Contreras X, Peterlin BM: Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 4(2), 123-133 (2008).
52. Duverger A, Jones J, May J et al.: Determinants of the establishment of human immunodeficiency virus type 1 latency. J. Virol. 83(7), 3078-3093 (2009).
53. + T lymphocytes. Nat. Med. 13(10), 1241-1247 (2007).
54. Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33(Suppl.), 245-254 (2003).
55. Harbers K, Schnieke A, Stuhlmann H, Jahner D, Jaenisch R: DNA methylation and gene expression: endogenous retroviral genome becomes infectious after molecular cloning. Proc. Natl Acad. Sci. USA 78(12), 7609-7613 (1981).
56. Lavie L, Kitova M, Maldener E, Meese E, Mayer J: CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERVK(HML-2). J. Virol. 79(2), 876-883 (2005).
57. Blazkova J, Trejbalova K, Gondois-Rey F et al.: CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 5(8), e1000554 (2009).
58. Verdin E: Dnase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1. J. Virol. 65(12), 6790-6799 (1991).
59. Verdin E, Paras P JR, van Lint C: Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J. 12(8), 3249-3259 (1993).
60. De Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370(Pt 3), 737-749 (2003).
61. Imai K, Okamoto T: Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J. Biol. Chem. 281(18), 12495-12505 (2006).
62. Tyagi M, Karn J: CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 26(24), 4985-4995 (2007).
63. Coull JJ, Romerio F, Sun JM et al.: The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J. Virol. 74(15), 6790-6799 (2000).
64. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC: NF-kb p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25(1), 139-149 (2006).
65. Marban C, Suzanne S, Dequiedt F et al.: Recruitment of chromatin-modifying enzymes by ctip2 promotes HIV-1 transcriptional silencing. EMBO J. 26(2), 412-423 (2007).
66. Jiang G, Espeseth A, Hazuda DJ, Margolis DM: c-Myc and sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J. Virol. 81(20), 10914-10923 (2007).
67. Roberts JD, Bebenek K, Kunkel TA: The accuracy of reverse transcriptase from HIV-1. Science 242(4882), 1171-1173 (1988).
68. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral vif protein. Nature 418(6898), 646-650 (2002).
69. Sundberg SA: High-throughput and ultra-high-throughput screening: solution-and cell-based approaches. Curr. Opin. Biotechnol. 11(1), 47-53 (2000).
70. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS: Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238(4828), 800-802 (1987).
71. Folks TM, Clouse KA, Justement J et al.: Tumor necrosis factor a induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl Acad. Sci. USA 86(7), 2365-2368 (1989).
72. Pomerantz RJ, Trono D, Feinberg MB, Baltimore D: Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 61(7), 1271-1276 (1990).
73. Krishnan V, Zeichner Sl: Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency. J. Virol. 78(17), 9458-9473 (2004).
74. Arlen PA, Brooks DG, Gao LY, Vatakis D, Brown HJ, Zack JA: Rapid expression of human immunodeficiency virus following activation of latently infected cells. J. Virol. 80(3), 1599-1603 (2006).
75. Emiliani S, Fischle W, Ott M, van Lint C, Amella CA, Verdin E: Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the u1 cell line. J. Virol. 72(2), 1666-1670 (1998).
76. Emiliani S, van Lint C, Fischle W et al.: A point mutation in the HIV-1 tat responsive element is associated with postintegration latency. Proc. Natl Acad. Sci. USA 93(13), 6377-6381 (1996).
77. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV: Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 tat fluctuations drive phenotypic diversity. Cell 122(2), 169-182 (2005).
78. Mccune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL: The SCID-hu mouse: murine model for the ana lysis of human hematolymphoid differentiation and function. Science 241(4873), 1632-1639 (1988).
79. Namikawa R, Weilbaecher KN, Kaneshima H, Yee EJ, Mccune JM: Long-term human hematopoiesis in the SCID-hu mouse. J. Exp. Med. 172(4), 1055-1063 (1990).
80. Aldrovandi GM, Feuer G, Gao L et al.: The SCID-hu mouse as a model for HIV-1 infection. Nature 363(6431), 732-736 (1993).
81. Bonyhadi ML, Rabin L, Salimi S et al.: HIV induces thymus depletion in vivo. Nature 363(6431), 728-732 (1993).
82. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, Mccune JM: Infection of the SCID-hu mouse by HIV-1. Science 242(4886), 1684-1686 (1988).
83. Brooks DG, Zack JA: Effect of latent human immunodeficiency virus infection on cell surface phenotype. J. Virol. 76(4), 1673-1681 (2002).
84. Brooks DG, Hamer DH, Arlen PA et al.: Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19(3), 413-423 (2003). ■ Utilization of the SCID-hu (Thy/Liv) mouse model for HIV latency to show that latently infected cells express little HIV mRNA, and can be induced with IL-7 or prostratin then killed with an anti-HIV immunotoxin.
85. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA: Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J. Virol. 76(24), 13077-13082 (2002).
86. Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA: Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 76(16), 8118-8123 (2002).
87. Brooks DG, Arlen PA, Gao L, Kitchen CM, Zack JA: Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc. Natl Acad. Sci. USA 100(22), 12955-12960 (2003).
88. Burke B, Brown HJ, Marsden MD, Bristol G, Vatakis DN, Zack JA: Primary cell model for activation-inducible human immunodeficiency virus. J. Virol. 81(14), 7424-7434 (2007).
89. + T cells. Blood 113(1), 58-65 (2009).
90. Kauder Se, Bosque A, Lindqvist A, Planelles V, Verdin E: Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5(6), e1000495 (2009).
91. Marini A, Harper JM, Romerio F: An in vitro system to model the establishment and reactivation of HIV-1 latency. J. Immunol. 181(11), 7713-7720 (2008).
92. + T-lymphocytes. Virology 355(2), 127-137 (2006).
93. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5(6), 651-655 (1999).
94. Prins JM, Jurriaans S, van Praag RM et al.: Immuno-activation with anti-CD3 and recombinant human I1-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13(17), 2405-2410 (1999).
95. Davey RT Jr, Bhat N, Yoder C et al.: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA 96(26), 15109-15114 (1999).
96. + T cells. AIDS 22(10), 1131-1135 (2008).
97. Lehrman G, Hogue IB, Palmer S et al.: Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366(9485), 549-555 (2005).
98. Siliciano JD, Lai J, Callender M et al.: Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 195(6), 833-836 (2007).
99. + T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. AIDS Res. Ther. 6, 15 (2009).
100. Stellbrink HJ, van Lunzen J, Westby M et al.: Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (cosmic trial). AIDS 16(11), 1479-1487 (2002).
101. + T cell depletion. J. Clin. Immunol. 21(3), 218-226 (2001).
102. Kulkosky J, Nunnari G, Otero M et al.: Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186(10), 1403-1411 (2002).
103. Lafeuillade A, Poggi C, Chadapaud S et al.: Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J. Acquir. Immune Defic. Syndr. (1999) 26(1), 44-55 (2001).
104. Bartlett JA, Miralles GD, Sevin AD et al.: Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. AIDS Res. Hum. Retroviruses 18(8), 535-543 (2002).
105. Gustafson KR, Cardellina JH 2nd, McMahon JB et al.: A nonpromoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J. Med. Chem. 35(11), 1978-1986 (1992).
106. Kulkosky J, Culnan DMm, Roman J et al.: Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98(10), 3006-3015 (2001). ■ Describes the potential merits of prostratin as an activator of latent HIV.
107. Williams SA, Chen LF, Kwon H et al.: Prostratin antagonizes HIV latency by activating NF-κb. J. Biol. Chem. 279(40), 42008-42017 (2004).
108. Wender PA, Kee JM, Warrington JM: Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science 320(5876), 649-652 (2008). ■ Description of the successful chemical synthesis of prostratin and analogs, which could allow the design of more specific and effective latency activators.
109. Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP: Short communication: Activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res. Hum. Retroviruses 25(9), 883-887 (2009).
110. + T cells. J. Infect. Dis. 197(8), 1162-1170 (2008).
111. Vlach J, Pitha PM: Hexamethylene bisacetamide activates the human immunodeficiency virus type 1 provirus by an NF-κb-independent mechanism. J. Gen. Virol. 74(Pt 11), 2401-2408 (1993).
112. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ: Immunotoxin treatment of cancer. Annu. Rev. Med. 58, 221-237 (2007).
113. Thrush GR, Lark LR, Clinchy BC, Vitetta ES: Immunotoxins: an update. Annu. Rev. Immunol. 14, 49-71 (1996).
114. Pincus SH, Fang H, Wilkinson RA, Marcotte TK, Robinson JE, Olson WC: In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection. J. Immunol. 170(4), 2236-2241 (2003).
115. Lueders KK, De Rosa SC, Valentin A, Pavlakis GN, Roederer M, Hamer DH: A potent anti-HIV immunotoxin blocks spreading infection by primary HIV type 1 isolates in multiple cell types. AIDS Res. Hum. Retroviruses 20(2), 145-150 (2004).
116. Kennedy PE, Bera TK, Wang QC et al.: Anti-HIV-1 immunotoxin 3b3(FV)-pe38: Enhanced potency against clinical isolates in human PBMCS and macrophages, and negligible hepatotoxicity in macaques. J. Leukoc. Biol. 80(5), 1175-1182 (2006).
117. Ramachandran RV, Katzenstein DA, Wood R, Batts DH, Merigan TC: Failure of short-term CD4-pe40 infusions to reduce virus load in human immunodeficiency virus-infected persons. J. Infect. Dis. 170(4), 1009-1013 (1994).
118. Davey RT Jr, Boenning CM, Herpin BR et al.: Use of recombinant soluble CD4 pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J. Infect. Dis. 170(5), 1180-1188 (1994).
119. Dornadula G, Zhang H, Vanuitert B et al.: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282(17), 1627-1632 (1999).
120. Maldarelli F, Palmer S, King MS et al.: ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 3(4), e46 (2007).
121. Palmer S, Maldarelli F, Wiegand A et al.: Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl Acad. Sci. USA 105(10), 3879-3884 (2008).
122. Sharkey ME, Teo I, Greenough T et al.: Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 6(1), 76-81 (2000).
123. Sharkey M, Triques K, Kuritzkes DR, Stevenson M: In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J. Virol. 79(8), 5203-5210 (2005).
124. + T cells. J. Virol. 80(13), 6441-6457 (2006).
125. Gendelman HE, Orenstein JM, Martin MA et al.: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167(4), 1428-1441 (1988).
126. Orenstein JM, Meltzer MS, Phipps T, Gendelman HE: Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. J. Virol. 62(8), 2578-2586 (1988).
127. Gartner S, Markovits P, Markovitz DM, Betts RF, Popovic M: Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA 256(17), 2365-2371 (1986).
128. Marsden MD, Xu J, Hamer D, Zack JA: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages. AIDS Res. Hum. Retroviruses 24(11), 1399-1404 (2008).
129. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM: Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18(8), 1101-1108 (2004).
130. Amado RG, Mitsuyasu RT, Rosenblatt JD et al.: Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a Phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum. Gene Ther. 15(3), 251-262 (2004).
131. Li MJ, Kim J, Li S et al.: Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing tar decoy. Mol. Ther. 12(5), 900-909 (2005).
132. An DS, Donahue RE, Kamata M et al.: Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc. Natl Acad. Sci. USA 104(32), 13110-13115 (2007).
133. + cells. Nat. Med. 15(3), 285-292 (2009).
134. Qin XF, An DS, Chen IS, Baltimore D: Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl Acad. Sci. USA 100(1), 183-188 (2003).